Brought to you by 
Intercept acquires FXR compound from U. of Perugia
06 Dec 2022
Executive Summary
In a cash and stock deal, start-up company Intercept Pharmaceuticals (develops drugs for chronic liver disease and metabolic disorders) acquired the FXR nuclear receptor agonist INT747 (formerly 6ECDCA) and related IP covering a portfolio of FXR compounds from Italy's University of Perugia and Roberto Pellicciari, PhD, a professor of medicinal chemistry at the university.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- Product Purchase
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Intercept acquires FXR compound from U. of Perugia
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice